Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Investor Presentation (March 2006)
20 slides from Adams Respiratory Therapeutics's investor presentation, Mar 22, 2006

Slide 1: Investor Meetings March 2006
Investor Meetings March 2006

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

Slide 3: Income Statement Overview
Income Statement Overview Includes $16.1 million tax benefit related to the future benefit of NOLs. Includes $2.5 million after-tax impact of the discretionary performance bonus. $110.3 $62.0 $160.2 $61.3 $14.0 Net Sales 79.6% 78.5% 80.6% 80.5% 62.6% Gross Margin % $37.5 34% $15.1 24% $44.4 28% $19.

Slide 4: Solid Financial Position
Solid Financial Position (in millions) As of As of Capitalization: June 30, 2005 Dec. 31, 2005 Cash, Cash Equivalents and Short- Term Investments $24.7 $153.4 Redeemable Convertible Preferred Stock $316.5 $ - Total Shareholders’ Equity (273.6) 188.9 Total Capitalization $42.8 $188.9 ] RESPIRATORY GS

Slide 5: Expanding Portfolio with Core Technology
$147.5 MM $49.8 MM Launched October 2005 Launch Expected in CY2006 Net Sales Trailing 12 Months as of 12/31/05 Expanding Portfolio with Core Technology Core technology: extended release guaifenesin Helps to thin phlegm (mucus) and bronchial secretions Useful when treating congestion: colds/allergies

Slide 6: Mucinex: Barriers to Entry
Mucinex(r): Barriers to Entry Additional Exclusivity (30 month stay upon competitive certification- par. IV) 2nd patent issued - 10/18/05 Both patents expire 2020 Rx Products withdrawn - Dec. 2003 Mucinex(r) NDA - (July 2002) Mucinex(r) DM NDA - (April 2004) Mucinex(r) D NDA - (June 2004) Drives con

Slide 7: Patent Reexamination
Patent Reexamination Patent Reexamination Process Table

Slide 8: Repeat Success with Mucinex Line Extensions
Competing Product Removal? Consumer Advertising Competing Product Removal? 9.2 MM Rx Repeat Success with Mucinex(r) Line Extensions Consumer Advertising November 2004 Competing Products Removed November 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $27 MM Rx market Consumer Advertisin

Slide 9: Mucinex: Market Share Gains
Mucinex(r): Market Share Gains Source: Information Resources, Inc. (IRI) weekly consumption data thru 3/12/06 (dollar sales) in cough/cold/allergy/sinus (c/c/a/s) category.

Slide 10: Mucinex: Total Brand Ranking
Mucinex(r): Total Brand Ranking Source: IRI 4, 12, 52 weeks ending 2/19/06 in c/c/a/s category. (a) Includes all Mucinex (r), Mucinex (r) DM and Mucinex (r) D skus. Brand Rank ($) Brand Rank ($) Brand Rank ($) Brand 52 Weeks Ended 12 Weeks Ended 4 Weeks Ended Claritin 1 5 5 Vicks 2 1 1 Tylenol 3 2 3

Slide 11: Mucinex: Market Share Dollar Sales
Mucinex(r): Market Share Dollar Sales Market Share Dollar Sales Market Share Dollar Sales Market Share Dollar Sales Brand 52 Weeks Ended 12 Weeks Ended 4 Weeks Ended Private Label 22.8% 20.5% 20.8% Claritin 10.0% 6.2% 6.8% Vicks 9.6% 12.5% 11.8% Tylenol 8.5% 7.9% 7.9% Robitussin 6.9% 7.8% 7.1% Mucin

Slide 12: Mucinex Unit Volume Reaches All-Time High
Mucinex(r) Unit Volume Reaches All-Time High Retail Consumption - Total Brand (20 ct equiv.) Source: Industry data week ending 3/12/06 04/05 Season 05/06 Season Peak season consumption more than doubled Surpassed last year's peak level by almost 200M units Experienced double peak in March Mr. Mucus(

Slide 13: Mucinex D Market Value
Thickened and excess mucus and respiratory congestion can exist in both the upper and lower airways Mucinex(r) D Market Value $2.0 billion market $2.9 billion market* Source: IRI 52-week period ending 12/25/05, F/D/Mx in c/c/a/s category.

Slide 14: Mucinex D Treats Excess Mucus
Mucinex(r) D Treats Excess Mucus Nasal congestion and sinus pressure sufferers are heavy category users and most likely to suffer throughout the year Excess mucus can further complicate symptoms among those suffering from nasal congestion and sinus pressure due to allergies Mucinex(r) D thins the ex

Slide 15: U.S. Development of Erdosteine
U.S. Development of Erdosteine In-licensed mucoregulator compound with a unique profile Published European studies showed significant improvements in: mucociliary clearance, mucus volume, flow characteristics and cough Approved in > 30 foreign markets; ~24 million patient exposures Phase II clinical

Slide 16: Financial Outlook: Consumption/Production Analysis
If Consumption is: @ 8% share $64 million @ 9% share $72 million @10% share $80 million Financial Outlook: Consumption/Production Analysis Annual IRI Retail Sales (1) $2.9 billion IRI Retail Sales @ 3/31/06 (2) $800 million IRI Retail Sales @ 3/12/06 (3) $739 million (1) IRI 52-weeks ended 12/25/05,

Slide 17: Financial Outlook: Backorder Analysis
Financial Outlook: Backorder Analysis Backorder @ 12/31/05 $20 million Assumed orders @ 3/31/06 (1) $65 million Total orders to fill @ 3/31/06(1) $85 million (1) Provided for illustrative purposes only Assumed factory shipments (1) ($72 - 75) million Backorder @ 3/31/06 (1) $10 -13 million

Slide 18: Planned Events for CY 2006
Planned Events for CY 2006 Initiate advertising campaign for Mucinex(r) D in advance of the spring allergy season (February 2006) Launch first maximum-strength Humibid(r) product (1H 2006) Introduce a line of products under the Mucinex(r) brand into the $300+ million pediatric segment (2H 2006) Cont

Slide 19: Future Growth Drivers
Future Growth Drivers Market Share Expansion Mucinex(r) D Allergy Mkt Revenues Children's Mucinex(r) Launch Humibid(r) Launch Exclusivity Decision on DM and D New Combo Products Erdosteine Acquisitions/ In-licensing Pricing Aggregate potential opportunity: $500 million + FY 2005 Net Revenue $160.2 M

Slide 20: Adams Respiratory Therapeutics
ADAMS RESPIRATORY ( THERAPEUTICS™ I®
Source: SEC EDGAR · 8-K filed Mar 22, 2006
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Investor Presentation (April 2007)60 slides · Apr 4, 2007
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)21 slides · Feb 8, 2007